MAIA Biotechnology, Inc. filings document the regulatory record for a clinical-stage oncology company developing ateganosine for non-small cell lung cancer. Form 8-K reports cover THIO-101 clinical updates, oncology conference materials, shareholder communications on the development pipeline, FDA Fast Track disclosure, and forward-looking risk language tied to investigational drug development.
The company’s filings also document capital structure and governance matters, including an underwritten common stock offering conducted under an effective Form S-3 shelf registration, the related underwriting agreement and use-of-proceeds disclosure, executive compensation actions, and annual meeting proxy matters such as director elections and auditor ratification.
MAIA Biotechnology director reports open-market share purchase. A company director filed a Form 4 disclosing the acquisition of 10,000 shares of MAIA Biotechnology common stock on 11/25/2025. The shares were purchased at a price of $0.9785 per share. Following this transaction, the director beneficially owns 399,483 shares of MAIA common stock, held directly.
MAIA Biotechnology, Inc. reported an insider share purchase by its Chief Executive Officer, director and 10% owner Vlad Vitoc. On 11/25/2025, he bought 10,500 shares of common stock at a weighted average price of $0.9661 per share, with individual trades ranging from $0.9606 to $0.9745. After this transaction, he directly holds 831,421 common shares. An additional 210,000 shares are held by his spouse, which he reports as indirectly beneficially owned but disclaims ownership beyond his economic interest.
MAIA Biotechnology director reports insider share purchases. Director Stan V. Smith filed a Form 4 showing two open-market purchases of MAIA common stock. On 11/24/2025, he bought 10,000 shares at a weighted average price of $0.99, with individual trades ranging from $0.9675 to $0.9899. On 11/25/2025, he bought another 15,000 shares at a weighted average price of $0.98, with trades between $0.9550 and $1.05. Following these transactions, he beneficially owns 1,349,289 shares indirectly through The Stan V. Smith Trust Dated 1993.
MAIA Biotechnology CEO share purchases were reported by Vlad Vitoc, who serves as Chief Executive Officer, Director and 10% owner of MAIA Biotechnology, Inc. (MAIA). On 11/21/2025, he bought 1,800 shares of common stock at a weighted average price of $0.92 per share, and on 11/24/2025 he bought an additional 10,000 shares at a price of $0.9891 per share.
Following these transactions, Vitoc directly beneficially owned 820,921 shares of MAIA common stock. The filing also notes 210,100 shares beneficially owned by his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest. The weighted average disclosure indicates the 1,800-share purchase was executed in multiple trades within a narrow price range between $0.9128 and $0.9235.
MAIA Biotechnology, Inc. reported under an 8-K that it issued a press release titled “MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025.” The company uses this filing to formally share that update with the market and attaches the full press release as an exhibit, incorporating it by reference.
The disclosure is presented as an “Other Events” item, meaning it is an informational update rather than a financial report or major transaction. The company also includes standard cautionary language that statements about its development programs, including the Ateganosine clinical program, are forward-looking and subject to significant risks and uncertainties.
MAIA Biotechnology, Inc. reported that its Chief Executive Officer, Vlad Vitoc, presented on telomere-targeting efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation. The company issued a press release titled “MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation,” which is attached as an exhibit and incorporated by reference.
The report also reiterates that any statements about future plans, development timelines, regulatory approvals, market potential, or other non-historical matters are forward-looking statements and subject to significant risks and uncertainties. MAIA highlights factors such as the progress and results of its preclinical and clinical studies, regulatory timing, manufacturing capabilities, market acceptance, market size and growth, and intellectual property protection as key areas that could cause actual outcomes to differ materially from these forward-looking comments.
MAIA Biotechnology reported a wider quarterly loss and flagged liquidity risk in its Q3 results. For the quarter ended September 30, 2025, the company posted a net loss of $8.9 million as operating expenses rose, driven by research and development.
Cash was $10.9 million with working capital of approximately $1.76 million. Management stated there is substantial doubt about the company’s ability to continue as a going concern within one year without additional financing. Operating cash outflow was $11.8 million for the nine months, partially offset by financing inflows of $13.1 million, including at-the-market share sales and multiple private placements.
Quarterly operating expenses were $9.36 million (R&D $6.36 million; G&A $3.00 million). The warrant liability decreased to $1.75 million, contributing to other income. Shares outstanding were 34.45 million at quarter-end; authorized common shares were increased to 150 million earlier in the year. As of November 7, 2025, common shares outstanding were 37,032,307.
MAIA Biotechnology reported two upcoming scientific presentations and made the materials available as exhibits. The company prepared a THIO-104 Phase 3 trial-in-progress poster for immune checkpoint inhibitor–resistant advanced NSCLC, presented at SITC 2025 on November 7, 2025, and a THIO-101 Phase 2 trial-in-progress poster for the same setting, presented on November 10, 2025.
The THIO-104 poster is filed as Exhibit 99.1 and the THIO-101 poster as Exhibit 99.2, with both to be posted on the company’s website on their respective presentation dates. The company notes these materials contain forward-looking statements.
MAIA Biotechnology filed an 8-K noting two updates. The company announced a trial-in-progress poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, highlighting its pipeline activities. MAIA also reported enrolling five patients from Taiwan and Turkey in the expansion phase of its THIO-101 Phase 2 trial.
MAIA Biotechnology reported under Regulation FD that it presented a scientific poster titled “Presentation 1: A Phase 2 Study of Ateganosine (THIO; 6‑thio‑2’-deoxyguanosine) in combination with immune checkpoint inhibitor in patients with advanced NSCLC: THIO‑101 Trial.”
The poster was presented at the AACR‑NCI‑EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts on October 24, 2025 and was posted to the company’s website the same day. The poster is furnished as Exhibit 99.1. The company notes the poster contains forward‑looking statements.